PAKHTOON 804

#US301ProbeOnGermanyDrugPricing #US301ProbeOnGermanyDrugPricing The U.S. has launched a Section 301 trade investigation into Germany's pharmaceutical pricing policies, arguing that Germany may be unfairly suppressing prices for innovative medicines and placing a burden on U.S. drugmakers. The probe was announced by U.S. Trade Representative Jamieson Greer on June 19, 2026. The investigation focuses on Germany's planned healthcare reforms, which were designed to reduce public healthcare spending and included measures that could lower drug reimbursement rates. U.S. officials claim persistent underpayment for innovative pharmaceuticals may be "unreasonable or discriminatory" under Section 301 of the Trade Act of 1974. A public comment period will begin on June 25, with a hearing expected in September. If the U.S. concludes that Germany's policies harm American commerce, the investigation could ultimately lead to retaliatory trade measures, including tariffs on German imports. Market Impact Positive for major U.S. pharmaceutical companies if Germany faces pressure to pay higher drug prices. Could increase trade tensions between the U.S. and Germany. Raises the possibility of new tariffs or other trade actions depending on the investigation's findings. Short: The U.S. is using Section 301 to examine whether Germany's drug-pricing policies unfairly disadvantage American pharmaceutical firms, with potential tariff action possible later this year.